Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia

References

• Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008 Mar 22;371(9617):1030–1043. PubMed PMID: 18358930.
   PubMed Web of Science ®Google Scholar
• Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015 Oct 15;373(16):1541–1552. PubMed PMID: 26465987.
   PubMed Web of Science ®Google Scholar
• Moricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010 Feb;24(2):265–284. PubMed PMID: 20010625.
   PubMed Web of Science ®Google Scholar
• Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010 Dec 11;376(9757):2009–2017. PubMed PMID: 21131038; PubMed Central PMCID: PMCPMC3010035.
   PubMed Web of Science ®Google Scholar
• Tallen G, Ratei R, Mann G, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol. 2010 May 10;28(14):2339–2347. PubMed PMID: 20385996.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Schrappe M, Bernardo ME, et al. How I treat relapsed childhood acute lymphoblastic leukemia. Blood. 2012 Oct 4;120(14):2807–2816. PubMed PMID: 22896001.
   PubMed Web of Science ®Google Scholar
• Ko RH, Ji L, Barnette P, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia consortium study. J Clin Oncol. 2010 Feb 1;28(4):648–654. PubMed PMID: 19841326; PubMed Central PMCID: PMCPMC2815999.
   PubMed Web of Science ®Google Scholar
• von Stackelberg A, Volzke E, Kuhl JS, et al. Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM study group. Eur J Cancer. 2011 Jan;47(1):90–97. PubMed PMID: 20970323.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Bargou RC, Nagorsen D, et al. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors. Leukemia. 2017 Apr;31(4):777–787. PubMed PMID: 28028314.
   PubMed Web of Science ®Google Scholar
• Salter AI, Pont MJ, Riddell SR. Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood. 2018 Jun 14;131(24):2621–2629. PubMed PMID: 29728402.
   PubMed Web of Science ®Google Scholar
• Velasquez MP, Bonifant CL, Gottschalk S. Redirecting T cells to hematological malignancies with bispecific antibodies. Blood. 2018 Jan 4;131(1):30–38. PubMed PMID: 29118005; PubMed Central PMCID: PMCPMC5755042.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gokbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015 Jan;16(1):57–66. PubMed PMID: 25524800.
   PubMed Web of Science ®Google Scholar
• von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016 Dec 20;34(36):4381–4389. PubMed PMID: 27998223.
   PubMed Web of Science ®Google Scholar
• Nisonoff A, Wissler FC, Lipman LN. Properties of the major component of a peptic digest of rabbit antibody. Science. 1960 Dec 9;132(3441):1770–1771. PubMed PMID: 13729245
   PubMed Web of Science ®Google Scholar
• Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature. 1985 Apr 18–24;314(6012):628–631. PubMed PMID: 2859527
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017 Feb/Mar;9(2):182–212. PubMed PMID: 28071970; PubMed Central PMCID: PMCPMC5297537
   PubMed Web of Science ®Google Scholar
• Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today. 2015 Jul;20(7):838–847. PubMed PMID: 25728220
   PubMed Web of Science ®Google Scholar
• Weiner GJ, Kostelny SA, Hillstrom JR, et al. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy. J Immunol. 1994 Mar 1;152(5):2385–2392. PubMed PMID: 8133049
   PubMed Web of Science ®Google Scholar
• Hombach A, Hombach AA, Abken H. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune response. Gene Ther. 2010 Oct;17(10):1206–1213. PubMed PMID: 20555360
   PubMed Web of Science ®Google Scholar
• Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol. 2015 Mar;93(3):290–296. PubMed PMID: 25367186; PubMed Central PMCID: PMCPMC4445461
   PubMed Web of Science ®Google Scholar
• Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009 Jun 15;69(12):4941–4944. PubMed PMID: 19509221.
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Hofmeister R, Brischwein K, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer. 2005 May 20;115(1):98–104. PubMed PMID: 15688411.
   PubMed Web of Science ®Google Scholar
• Del Nagro CJ, Otero DC, Anzelon AN, et al. CD19 function in central and peripheral B-cell development. Immunol Res. 2005;31(2):119–131. PubMed PMID: 15778510
   PubMed Web of Science ®Google Scholar
• Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012 Nov 29;1(1):36. PubMed PMID: 23210908; PubMed Central PMCID: PMCPMC3520838.
   PubMedGoogle Scholar
• Fujimoto M, Poe JC, Inaoki M, et al. CD19 regulates B lymphocyte responses to transmembrane signals. Semin Immunol. 1998 Aug;10(4):267–277. PubMed PMID: 9695183.
   PubMed Web of Science ®Google Scholar
• Baracho GV, Miletic AV, Omori SA, et al. Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation. Curr Opin Immunol. 2011 Apr;23(2):178–183. PubMed PMID: 21277760; PubMed Central PMCID: PMCPMC3070849.
   PubMed Web of Science ®Google Scholar
• Dreier T, Lorenczewski G, Brandl C, et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer. 2002 Aug 20;100(6):690–697. PubMed PMID: 12209608.
   PubMed Web of Science ®Google Scholar
• Leone P, Shin EC, Perosa F, et al. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst. 2013 Aug 21;105(16):1172–1187. PubMed PMID: 23852952.
   PubMedGoogle Scholar
• Rogala B, Freyer CW, Ontiveros EP, et al. Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies. Expert Opin Biol Ther. 2015 Jun;15(6):895–908. PubMed PMID: 25985814; PubMed Central PMCID: PMCPMC4994468.
   PubMed Web of Science ®Google Scholar
• Wolach O, Stone RM. Blinatumomab for the treatment of philadelphia chromosome-negative, precursor B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2015 Oct 1;21(19):4262–4269. 10.1158/1078-0432.CCR-15-0125. PubMed PMID: 26283683
   PubMed Web of Science ®Google Scholar
• Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012 Jun 28;119(26):6226–6233. PubMed PMID: 22592608.
   PubMed Web of Science ®Google Scholar
• Zhu M, Wu B, Brandl C, et al. Blinatumomab, a bispecific T-cell engager (BiTE((R))) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications. Clin Pharmacokinet. 2016 Oct;55(10):1271–1288. 10.1007/s40262-016-0405-4. PubMed PMID: 27209293
   PubMed Web of Science ®Google Scholar
• Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008 Aug 15;321(5891):974–977. PubMed PMID: 18703743.
   PubMed Web of Science ®Google Scholar
• Zugmaier G, Topp MS, Alekar S, et al. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J. 2014 Sep;5(4):244. PubMed PMID: 25192414; PubMed Central PMCID: PMCPMC4183773.
   PubMed Web of Science ®Google Scholar
• Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011 Jun 20;29(18):2493–2498. PubMed PMID: 21576633.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gokbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012 Dec 20;120(26):5185–5187. PubMed PMID: 23024237.
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Zugmaier G, Klinger M, et al. Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia. Haematologica. 2017 Apr;102(4):e132–e135. PubMed PMID: 28082340; PubMed Central PMCID: PMCPMC5395124.
   PubMed Web of Science ®Google Scholar
• Gokbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018 Apr 5;131(14):1522–1531. PubMed PMID: 29358182; PubMed Central PMCID: PMCPMC6027091.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gokbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014 Dec 20;32(36):4134–4140. PubMed PMID: 25385737.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Stein A, Gokbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017 Mar 2;376(9):836–847. PubMed PMID: 28249141; PubMed Central PMCID: PMCPMC5881572.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Boissel N, Chevallier P, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a Phase II, single-arm, multicenter study. J Clin Oncol. 2017 Jun 1;35(16):1795–1802. PubMed PMID: 28355115.
   PubMed Web of Science ®Google Scholar
• Handgretinger R, Zugmaier G, Henze G, et al. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia. 2011 Jan;25(1):181–184. PubMed PMID: 20944674.
   PubMed Web of Science ®Google Scholar
• Schlegel P, Lang P, Zugmaier G, et al. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica. 2014 Jul;99(7):1212–1219. PubMed PMID: 24727818; PubMed Central PMCID: PMCPMC4077083.
   PubMed Web of Science ®Google Scholar
• Bader P, Kreyenberg H, Gh H, et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM study group. J Clin Oncol. 2009 Jan 20;27(3):377–384. PubMed PMID: 19064980.
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res. 2011 May 15;317(9):1255–1260. PubMed PMID: 21419116.
   PubMed Web of Science ®Google Scholar
• Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013 Jun 27;121(26):5154–5157. PubMed PMID: 23678006; PubMed Central PMCID: PMCPMC4123427.
   PubMed Web of Science ®Google Scholar
• Frey N. Cytokine release syndrome: who is at risk and how to treat. Best Pract Res Clin Haematol. 2017 Dec;30(4):336–340. PubMed PMID: 29156206
   PubMed Web of Science ®Google Scholar
• Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188–195. PubMed PMID: 24876563; PubMed Central PMCID: PMCPMC4093680.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012 Mar 22;119(12):2709–2720. PubMed PMID: 22160384; PubMed Central PMCID: PMCPMC3327450.
   PubMed Web of Science ®Google Scholar
• Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell therapy: 25years in the making. Blood Rev. 2016 May;30(3):157–167. PubMed PMID: 26574053
   PubMed Web of Science ®Google Scholar
• Barrett DM, Teachey DT, Grupp SA. Toxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr. 2014 Feb;26(1):43–49. PubMed PMID: 24362408; PubMed Central PMCID: PMCPMC4198063
   PubMed Web of Science ®Google Scholar
• Assi R, Kantarjian H, Short NJ, et al. Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed philadelphia chromosome-positive leukemia. Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):897–901. PubMed PMID: 28927784.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Song J, Stiller T, et al. Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2017 Sep;92(9):858–865. PubMed PMID: 28494518.
   PubMed Web of Science ®Google Scholar
• Duell J, Dittrich M, Bedke T, et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia. 2017 Oct;31(10):2181–2190. PubMed PMID: 28119525; PubMed Central PMCID: PMCPMC5629361.
   PubMed Web of Science ®Google Scholar
• Sotillo E, Barrett DM, Black KL, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 Immunotherapy. Cancer Discov. 2015 Dec;5(12):1282–1295. PubMed PMID: 26516065; PubMed Central PMCID: PMCPMC4670800.
   PubMed Web of Science ®Google Scholar
• Mejstrikova E, Hrusak O, Borowitz MJ, et al. CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment. Blood Cancer J. 2017 Dec 20;7(12):659. 10.1038/s41408-017-0023-x. PubMed PMID: 29259173; PubMed Central PMCID: PMCPMC5802535.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Song JY. Extramedullary relapse of KMT2A(MLL)-rearranged acute lymphoblastic leukemia with lineage switch following blinatumomab. Blood. 2018 May 31;131(22):2507. PubMed PMID: 29853461.
   PubMed Web of Science ®Google Scholar
• Zoghbi A, Zur Stadt U, Winkler B, et al. Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement. Pediatric Blood & Cancer. 2017 Nov;64(11). PubMed PMID: 28453885. DOI:10.1002/pbc.26594.
   PubMed Web of Science ®Google Scholar
• Braig F, Brandt A, Goebeler M, et al. Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood. 2017 Jan 5;129(1):100–104. PubMed PMID: 27784674.
   PubMed Web of Science ®Google Scholar
• Reusch U, Duell J, Ellwanger K, et al. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs. 2015;7(3):584–604. PubMed PMID: 25875246; PubMed Central PMCID: PMCPMC4622993
   PubMed Web of Science ®Google Scholar
• Fajardo CA, Guedan S, Rojas LA, et al. Oncolytic adenoviral delivery of an EGFR-targeting T-cell engager improves antitumor efficacy. Cancer Res. 2017 Apr 15;77(8):2052–2063. PubMed PMID: 28143835.
   PubMed Web of Science ®Google Scholar
• Aliperta R, Cartellieri M, Feldmann A, et al. Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts. Blood Cancer J. 2015 Sep;18(5):e348. PubMed PMID: 26383821; PubMed Central PMCID: PMCPMC4648523.
   PubMed Web of Science ®Google Scholar
• Velasquez MP, Torres D, Iwahori K, et al. T cells expressing CD19-specific engager molecules for the immunotherapy of CD19-positive malignancies. Sci Rep. 2016 Jun;3(6):27130. PubMed PMID: 27255991; PubMed Central PMCID: PMCPMC4891739.
   PubMed Web of Science ®Google Scholar
• Buitenkamp TD, Izraeli S, Zimmermann M, et al. Acute lymphoblastic leukemia in children with down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood. 2014 Jan 2;123(1):70–77. PubMed PMID: 24222333; PubMed Central PMCID: PMCPMC3879907.
   PubMed Web of Science ®Google Scholar
• Fischer U, Forster M, Rinaldi A, et al. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat Genet. 2015 Sep;47(9):1020–1029. PubMed PMID: 26214592; PubMed Central PMCID: PMCPMC4603357.
   PubMed Web of Science ®Google Scholar